Table 2.
Sulfadoxine-pyrimethamine treatment outcomes, 1998-2002. Values are numbers (percentages)
|
Study year
|
||||||
|---|---|---|---|---|---|---|
| Outcomes | 1998 | 1999 | 2000 | 2001 | 2002 | Total |
| Therapeutic outcomes at 14 days | (n=77) | (n=146) | (n=216) | (n=386) | (n=138) | (n=963) |
| Adequate clinical response | 66 (86) | 120 (82) | 177 (82) | 308 (80) | 114 (83) | 785 (82) |
| Late treatment failure | 1 (1) | 5 (3) | 13 (6) | 15 (4) | 6 (4) | 40 (4) |
| Early treatment failure | 10 (13) | 21 (14) | 26 (12) | 63 (16) | 18 (13) | 138 (14) |
| Therapeutic outcomes at 28 days | (n=66) | (n=117) | (n=196) | (n=307) | (n=103) | (n=789) |
| Adequate clinical response | 48 (73) | 81 (69) | 144 (74) | 196 (64) | 62 (60) | 531 (67) |
| Late treatment failure | 8 (12) | 15 (13) | 26 (13) | 48 (16) | 23 (22) | 120 (15) |
| Early treatment failure | 10 (15) | 21 (18) | 26 (13) | 63 (21) | 18 (18) | 138 (18) |
| Parasitological outcomes at 14 days | (n=82) | (n=151) | (n=243) | (n=425) | (n=153) | (n=1054) |
| Sensitive | 60 (73) | 96 (64) | 159 (65) | 267 (63) | 94 (61) | 676 (64) |
| Resistant at the RI level | 11 (13) | 37 (25) | 38 (16) | 65 (15) | 29 (19) | 180 (17) |
| Resistant at the RII level | 2 (2) | 1 (1) | 22 (9) | 30 (7) | 12 (8) | 67 (6) |
| Resistant at the RIII level | 9 (11) | 17 (11) | 24 (10) | 63 (15) | 18 (12) | 131 (12) |
| Parasitological outcomes at 28 days | (n=77) | (n=149) | (n=236) | (n=388) | (n=143) | (n=993) |
| Sensitive | 29 (38) | 49 (33) | 93 (39) | 130 (34) | 38 (27) | 339 (34) |
| Resistant at the RI level | 37 (48) | 82 (55) | 96 (41) | 164 (42) | 74 (52) | 453 (46) |
| Resistant at the RII level | 2 (3) | 1 (1) | 23 (10) | 31 (8) | 13 (9) | 70 (7) |
| Resistant at the RIII level | 9 (12) | 17 (11) | 24 (10) | 63 (16) | 18 (13) | 131 (13) |
RI-RIII: see text for definitions.